Cigna remains a 'Hold' due to valuation concerns and systemic US healthcare risks despite recent sector underperformance.
TrumpRx, the Trump administration’s much-anticipated direct-to-consumer drug platform, is expected to launch on Thursday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results